Physician profile
Wei Wang
NPI 1972528032
$26,057.56
in general payments reported to CMS, 2019-2025
69 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,170 · 2020: $4,800 · 2021: $5,183 · 2022: $4,245 · 2023: $2,459 · 2024: $2,313 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,659.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,866.26 | 2019-2025 | Ubrelvy, Linzess, Vraylar |
| Glaxosmithkline, LLC. | $2,312.20 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,259.45 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals Lp | $2,005.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Horizon Therapeutics Plc | $1,220.58 | 2019-2022 | |
| Amgen INC. | $1,117.90 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $1,074.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $1,019.28 | 2020-2023 | |
| Pfizer INC. | $1,018.53 | 2019-2025 | |
| Novo Nordisk INC | $1,006.17 | 2020-2024 | Ozempic, Rybelsus |
| Allergan, INC. | $773.35 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $678.83 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $578.13 | 2019-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $497.48 | 2019-2024 | Verquvo, Lagevrio |
| Biohaven Pharmaceutical Holding Company Ltd. | $434.18 | 2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.